Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC cut its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,886,702 shares of the company's stock after selling 114,499 shares during the quarter. Aristotle Atlantic Partners LLC owned approximately 1.96% of Adaptive Biotechnologies worth $17,306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC lifted its stake in Adaptive Biotechnologies by 149.5% in the third quarter. Barclays PLC now owns 230,177 shares of the company's stock worth $1,180,000 after acquiring an additional 137,936 shares during the period. B. Riley Wealth Advisors Inc. raised its holdings in shares of Adaptive Biotechnologies by 48.1% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,000 shares of the company's stock valued at $102,000 after purchasing an additional 6,500 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $59,000. SG Americas Securities LLC boosted its stake in shares of Adaptive Biotechnologies by 11.7% during the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company's stock valued at $275,000 after purchasing an additional 4,799 shares in the last quarter. Finally, Impact Partnership Wealth LLC increased its holdings in Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company's stock valued at $114,000 after buying an additional 1,539 shares during the period. Institutional investors own 99.17% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on ADPT shares. Morgan Stanley upped their target price on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Monday. The Goldman Sachs Group upped their price objective on Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday. Scotiabank lifted their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 13th. Finally, Piper Sandler reissued an "overweight" rating and set a $11.00 price target (up from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

Insider Transactions at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 211,160 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total value of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,901,958.50. This trade represents a 7.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Francis Lo sold 20,875 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total value of $145,916.25. Following the sale, the insider now owns 332,846 shares in the company, valued at approximately $2,326,593.54. The trade was a 5.90 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 826,013 shares of company stock worth $6,543,452. Company insiders own 6.20% of the company's stock.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT traded up $0.19 during mid-day trading on Monday, hitting $10.03. 5,673,885 shares of the company's stock traded hands, compared to its average volume of 1,562,960. The company has a fifty day moving average of $7.76 and a 200 day moving average of $6.91. Adaptive Biotechnologies Co. has a twelve month low of $2.99 and a twelve month high of $10.28. The company has a market capitalization of $1.52 billion, a P/E ratio of -9.20 and a beta of 1.75.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.08. The firm had revenue of $52.44 million during the quarter, compared to analyst estimates of $42.13 million. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. Adaptive Biotechnologies's revenue was up 25.2% on a year-over-year basis. During the same period last year, the firm posted ($0.33) EPS. On average, research analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.